Skip to main content
Edition No. 102 · GlobalEst. 2026
S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,881.55+0.91%DAX26,598.64+1.26%Nikkei 22559,069.62-3.56%Hang Seng23,753.84-2.84%EUR/USD1.0990-1.60%GBP/USD1.3174-1.31%Gold3,855.60-3.62%Crude Oil85.41-1.29%Bitcoin64,539.55-5.44%S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,881.55+0.91%DAX26,598.64+1.26%Nikkei 22559,069.62-3.56%Hang Seng23,753.84-2.84%EUR/USD1.0990-1.60%GBP/USD1.3174-1.31%Gold3,855.60-3.62%Crude Oil85.41-1.29%Bitcoin64,539.55-5.44%

QurAlis Receives FDA Clearance to Begin Pivotal ALS Clinical Trial

New precision therapy QRL-201 shows promise in slowing disease progression by targeting protein expression in patients with amyotrophic lateral sclerosis.

By Planet Earth News Medicine Desk· Published 2026-11-17· 3 min read
PENN Explainer

Hear this story explained in 90 seconds.

The U.S. Food and Drug Administration has officially cleared an Investigational New Drug application for QRL-201, a new therapy designed to treat amyotrophic lateral sclerosis. This regulatory milestone allows the developer, QurAlis Corporation, to move forward with a pivotal clinical trial in the United States. The upcoming study, known as CONQUR, is expected to begin in the first half of 2027. This development marks a significant step in the search for treatments that can modify the progression of this neurodegenerative disease. QRL-201 is a first-in-class antisense oligonucleotide precision therapeutic. Its primary goal is to restore the expression of a protein called STATHMIN-2 in patients living with ALS. This protein is essential for maintaining healthy nerve cells and muscle innervation, but it is often downregulated in those affected by the condition. By targeting the underlying biological mechanisms of the disease, researchers hope to improve long-term patient outcomes. The FDA clearance follows positive results from the dose-range finding phase of the ANQUR clinical trial. In this study, researchers observed that QRL-201 effectively slowed disease progression by 50 percent in participants receiving a high dose. These findings were measured using the ALS Functional Rating Scale-Revised, a standard tool for tracking the condition. The data provided a strong foundation for the decision to advance the drug into larger, pivotal testing. Beyond functional improvements, the trial also tracked specific biomarkers of nerve damage. Participants treated with the drug showed significant reductions in levels of phosphorylated neurofilament heavy and plasma neurofilament light in their bodily fluids. These proteins are widely recognized as indicators of axonal damage in the nervous system. The observed decreases suggest that the therapy may be successfully protecting nerve fibers from further harm. Kasper Roet, the CEO and co-founder of QurAlis, expressed optimism regarding the regulatory progress. He stated that the clearance marks an important milestone for the company and highlights the agency's support for research into rare diseases. The company plans to share more detailed information about the design and scope of the CONQUR trial early next year. While the U.S. trial prepares to launch, the ANQUR study continues in other parts of the world. The open-label extended dosing phase of the research is currently active in Canada, the United Kingdom, and the European Union. This ongoing work allows researchers to gather more data on the long-term safety and effectiveness of the treatment. Merit E. Cudkowicz, the director of the Sean M. Healey and AMG Center for ALS, noted that the current findings justify further investigation. She emphasized that the results provide a promising path forward for individuals living with sporadic forms of the disease. As the medical community looks toward 2027, the focus remains on confirming these early benefits in a larger, more diverse patient population.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine